AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results from the global Phase III DESTINY-Breast05 trial and represents the tenth Breakthrough Therapy Designation for Enhertu across oncology indications.

The regulatory milestone arrives at a pivotal moment for post-neoadjuvant strategy in breast cancer, a treatment space where residual disease has long been associated with heightened risk of metastasis and limited progress beyond the current standard-of-care agent, trastuzumab emtansine (T-DM1). The new data positions Enhertu as a potential replacement for T-DM1 in this high-risk, early-stage setting.

Why Enhertu’s FDA breakthrough tag matters more in early-stage disease than in metastatic settings

While Enhertu has already transformed treatment algorithms in metastatic HER2-positive and HER2-low breast cancer, this new designation extends its clinical promise into a curative-intent population. Patients with HER2-positive early breast cancer who fail to achieve pathologic complete response after neoadjuvant therapy remain a clinically vulnerable group. Despite receiving post-neoadjuvant T-DM1, approximately one in five patients still experiences disease recurrence or death, with little protection against central nervous system progression.

DESTINY-Breast05 directly challenges that benchmark. In this randomized, multicenter trial, Enhertu was shown to provide superior invasive disease-free survival compared to T-DM1. If approved for this indication, Enhertu could redefine what it means to consolidate curative treatment in high-risk early-stage HER2-positive disease. That shift could significantly reduce the clinical and emotional toll associated with metastatic relapse, where five-year survival plummets from nearly 90 percent in early-stage disease to around 30 percent once metastases occur.

How AstraZeneca and Daiichi Sankyo are methodically pushing Enhertu earlier in the treatment timeline

The progression of Enhertu from late-stage rescue therapy into early disease reflects a deliberate and ambitious lifecycle management plan by AstraZeneca PLC and Daiichi Sankyo. The post-neoadjuvant setting is only the latest in a series of HER2 niches that the drug has entered in rapid succession, including approvals for HER2-low and HER2-ultralow breast cancers, HER2-mutant lung cancer, gastric cancer, and even pan-tumor use in HER2-expressing solid tumors.

This breakthrough designation follows the earlier success of the DESTINY-Breast03 and DESTINY-Breast04 trials in metastatic disease and complements the ongoing regulatory review of Enhertu in the neoadjuvant setting via the DESTINY-Breast11 trial. Together, these trials map a comprehensive route through the HER2-positive breast cancer journey, from pre-surgical systemic therapy to post-surgical risk mitigation.

The companies’ strategy appears to involve building seamless dominance across disease stages while supporting that expansion with robust global manufacturing capabilities and a clinically diverse trial portfolio. Enhertu is now one of the few antibody-drug conjugates with a plausible path toward becoming a backbone therapy in early-stage solid tumors.

Why the DESTINY-Breast05 trial marks a turning point for the post-neoadjuvant space

The DESTINY-Breast05 trial enrolled 1,635 patients across Asia, Europe, North America, Oceania, and South America. It was designed as a head-to-head comparison of Enhertu against T-DM1 in patients with HER2-positive early breast cancer who had residual invasive disease in the breast or lymph nodes following neoadjuvant therapy. Participants were characterized as high risk either by initial inoperability or by residual nodal disease post-treatment.

The trial’s primary endpoint was investigator-assessed invasive disease-free survival, with secondary endpoints that included overall survival, distant recurrence-free interval, brain metastases-free interval, and safety. Although specific hazard ratios and statistical details remain under FDA embargo, the drug’s Breakthrough Therapy Designation confirms that Enhertu demonstrated meaningful clinical benefit over T-DM1.

Importantly, Enhertu’s mechanism of action may explain its advantage. The molecule combines a HER2 monoclonal antibody with a topoisomerase I inhibitor payload using a tetrapeptide-based cleavable linker, resulting in a highly potent cytotoxic effect even in tumors with low HER2 expression. This contrasts with T-DM1, which uses a less potent maytansine payload and relies more heavily on high HER2 expression for therapeutic efficacy.

What could complicate Enhertu’s entry into early-stage breast cancer protocols

Despite its demonstrated clinical power, Enhertu’s broader adoption in the early-stage setting will likely hinge on payer acceptance, toxicity profile, and long-term risk-benefit ratios. One major concern is the drug’s association with interstitial lung disease and pneumonitis, which have been observed across multiple trials, particularly in later-line treatment settings. The acceptability of those risks in curative-intent therapy will be a key point of FDA scrutiny.

Reimbursement may also become a barrier, particularly if Enhertu is priced similarly to its metastatic indication. Payers and health technology assessment bodies may demand robust cost-effectiveness modeling that justifies its use over T-DM1, especially in systems already burdened by oncology drug spending.

In parallel, clinicians are likely to weigh whether Enhertu’s safety and tolerability in a healthier early-stage population is meaningfully different from its profile in metastatic patients. This will require long-term follow-up data, especially in terms of late adverse events, quality of life impact, and durability of benefit.

What regulatory watchers, clinicians, and the oncology industry are watching next

With Enhertu now advancing in both neoadjuvant (DESTINY-Breast11) and post-neoadjuvant (DESTINY-Breast05) indications, the sequencing of therapies could become a critical question. If Enhertu displaces both current standards, the issue of optimal dosing duration, toxicity management, and potential for drug resistance in future relapse settings will need further study.

Another open question is the role of Enhertu in HER2-low and HER2-ultralow early breast cancer populations. The DESTINY-Breast06 trial has already secured metastatic approval in those settings, but translating those results into early disease requires clearer diagnostic precision and biomarker standardization. With pathologists still adjusting to evolving HER2 classification criteria, clinical implementation could face logistical hurdles.

Regulators may also consider the impact of combining Enhertu with other emerging agents. AstraZeneca PLC has active trials combining ADCs with checkpoint inhibitors, AKT inhibitors like capivasertib, and oral SERDs such as camizestrant. Future early-stage regimens could include dual-modality approaches that further increase cure rates in subgroups like hormone receptor-positive, HER2-low tumors.

Finally, manufacturing scale and global supply chains will be under pressure if Enhertu receives early-stage approval. The drug’s complex production process, involving linker-payload chemistry and cold-chain requirements, will need to keep pace with dramatically increased demand if uptake matches expectations in curative settings.

  antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, DESTINY-Breast05, Enhertu, FDA, HER2-positive breast cancer, oncology, post-neoadjuvant therapy, trastuzumab deruxtecan